Deals
Lilly Pays $115M Upfront in Insilico AI Deal Worth Up to $2.75B
Eli Lilly paid $115M upfront for an AI collaboration with Insilico Medicine worth up to $2.75B, with milestone math that heavily favors Lilly.
Latest — Page 25
Legal
DOJ Backs Pharma on 340B, Leaving Safety-Net Hospitals Exposed
The DOJ reversed course to back pharma in the 340B contract pharmacy dispute, leaving safety-net hospitals without a federal ally.
Legal
Trump Signs 100% Tariff Order on Imported Drugs
Trump signed an executive order imposing 100% tariffs on drug imports from countries without U.S. trade deals, effective within months.
Deals
Blackstone Raises New Fund as Two Pharma Giants Close March Megadeals
Two pharma giants closed megadeals in March while Blackstone raised a new fund — more dry powder chasing the same targets means multiples only go one way.
Deals
Biogen Drops $5.6B for Apellis at 140% Premium, Shares Fall
Biogen acquires Apellis for $5.6B at a near 140% premium, adding Syfovre and Empaveli to offset a fading MS franchise ahead of pharma's patent cliff.
FDA
FDA Clears Novocure's Pancreatic Cancer Device in First-Ever Approval
FDA approved Novocure's Optune Pax for locally advanced pancreatic cancer, the first device cleared for it, adding ~2 months to survival over standard chemo.
FDA
FDA Clears 7.2mg Wegovy HD for Novo Nordisk in 54-Day Sprint
FDA cleared Novo Nordisk's 7.2mg Wegovy HD in 54 days under its national priority program, pushing the GLP-1's efficacy ceiling higher.
fda
FDA
Lilly's Oral GLP-1 Pill Cleared in 50 Days, Fastest NME Since 2002
Eli Lilly's oral GLP-1 pill orforglipron approved in 50 days under the FDA's CNPV pilot — the fastest new molecular entity approval since 2002.
FDA
Trump's 100% Pharma Tariff: Who Pays, Who Gets Out
Trump's 100% tariff on branded pharma imports creates a hard deadline: cut MFN pricing deals and reshore, or face full tariffs by 2030.
You've reached the end of the archive.
Want the next stories in your inbox? Subscribe to the newsletter